Compare Deutsche Bank AG (DB) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deutsche Bank AG vs Cassava Sciences Inc — how do they compare? Deutsche Bank AG trades at $35.81 (market cap $68.51B), while Cassava Sciences Inc trades at $1.09 (market cap $52.66M). The key difference: Deutsche Bank AG is far larger — about 1301× Cassava Sciences Inc's market cap, and Deutsche Bank AG pays a 3.26% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| DB | FLNA | |
|---|---|---|
Market Cap | $68.51B | $52.66M |
Sector | Financials | Health |
52-Week High | $40.33 | $4.64 |
52-Week Low | $28.37 | $1.09 |
Dividend Yield | 3.26% | — |
Enterprise Value | — | -$33.92M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deutsche Bank (DB) trades at $35.24, down 1.48% on the day, with a bullish technical signal from moving averages and a neutral stance from oscillators. The stock shows attractive valuation metrics with a P/E of 9.79 and P/B of 0.76. Recent quarterly earnings have consistently beaten expectations, and the company announced a $1.00 dividend for H1-26. However, 2024 cash flow was negative $33.10 billion, though it improved to a positive $7.6 billion in 2025.
The outlook is mixed; strong profitability and earnings beats support upside, but regulatory scrutiny and volatile cash flows pose risks. Analyst consensus is cautious with 57.58% hold ratings. The stock's low valuation may appeal to value investors, yet headline risks from recent legal searches require monitoring.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Deutsche Bank AG
In July 2019, Deutsche Bank announced another restructuring plan hoping to revitalize revenue, reduce costs, and return to profitability. The largest moving pieces of the new plan is the full exit of global equity sales & trading, the scaling back of its fixed income business, as well as 18,000 FTE reductions until 2022. The remaining core business segments include private banking, corporate banking, asset management, and investment banking.
Read more on DB →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
